CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (unaudited) - USD ($) $ in Thousands		9 Months Ended
		Dec. 31, 2017	Dec. 31, 2016
Cash flows from operating activities:
Net income		$ 108,657	$ 27,731
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation and amortization		459,032	340,925
Deferred income taxes		67,555	(52,215)
Share-based compensation expense related to equity incentive plans		70,021	106,089
Loss on settlement of convertible debt		15,966	0
Amortization of debt discount on convertible debt		79,017	36,907
Amortization of debt issuance costs		4,952	3,182
Losses on equity method investments		167	167
Gains on sale of assets		(5,421)	(78)
Losses on write-down of fixed assets		60	1,278
Impairment of intangible assets		252	10,226
Realized losses on available-for-sale investment		0	89
Realized gains on equity method investment		0	(468)
Impairment of available-for-sale investment		0	1,433
Amortization of premium on available-for-sale investments		531	5
Changes in operating assets and liabilities, excluding impact of acquisitions:
Increase in accounts receivable		(74,762)	(43,551)
(Increase) decrease in inventories		(70,183)	220,674
Increase in deferred income on shipments to distributors		42,890	110,827
Increase (decrease) in accounts payable and accrued liabilities		41,782	(22,261)
Change in other assets and liabilities		15,663	(18,780)
Change in income tax payable		303,903	5,364
Operating cash flows related to discontinued operations		0	9,348
Net cash provided by operating activities		1,060,082	736,892
Cash flows from investing activities:
Purchases of available-for-sale investments		(1,338,140)	(35,147)
Maturities of available-for-sale investments		520,086	350
Sales of available-for-sale investments		0	470,215
Sale of equity method investment		0	468
Acquisition of Atmel, net of cash acquired		0	(2,747,516)
Investments in other assets		(5,384)	(9,597)
Proceeds from sale of assets		10,289	23,069
Capital expenditures		(148,412)	(52,338)
Net cash used in investing activities		(961,561)	(2,350,496)
Cash flows from financing activities:
Payments on settlement of convertible debt	[1]	(73,421)	0
Repayments of revolving loan under credit facility	[1]	(187,000)	(1,078,500)
Proceeds from borrowings on revolving loan under credit facility	[1]	187,000	1,517,000
Deferred financing costs	[1]	(1,208)	0
Payment of cash dividends	[1]	(252,360)	(232,847)
Proceeds from sale of common stock	[1]	26,576	28,893
Tax payments related to shares withheld for vested restricted stock units	[1]	(34,126)	(48,161)
Capital lease payments	[1]	(587)	(587)
Net cash (used in) provided by financing activities	[1]	(335,126)	185,798
Effect of foreign exchange rate changes on cash and cash equivalents		0	(1,007)
Net decrease in cash and cash equivalents		(236,605)	(1,428,813)
Cash and cash equivalents at beginning of period		908,684	2,092,751
Cash and cash equivalents at end of period		$ 672,079	$ 663,938

[1] During the nine months ended December 31, 2017, the Company issued $111.3 million principal amount of 2017 Junior Notes and 3.2 million shares of common stock in exchange for $111.3 million principal amount of 2007 Junior Notes. Refer to Note 13 Debt and Credit Facility for further discussion.